中国临床药理学杂志2025，Vol.41Issue(14)：1983-1987,5.DOI:10.13699/j.cnki.1001-6821.2025.14.007
重组人血管内皮抑制素治疗老年局部晚期食管癌患者的临床研究
Clinical trial of recombinant human endostatin in the treatment of elderly patients with locally advanced esophageal cancer
摘要
Abstract
Objective To investigathe the clinical efficacy and safety of recombinant human endostatin injection(END)and tegafur/gimeracil/oteracil potassium(OP)on the basis of radiotherapy in the treatment of elderly patients with locally advanced esophageal cancer(LAEC).Methods Patients with LAEC were grouped according to corhort methods.group A was treated with END(30 mg per day for 1 week,stopped for 2 weeks for 2 cycles)on the basis of radiotherapy.group B was treated with OP(40-60 mg·(m2)-1,twice a day for 2 weeks,stopped for 1 week,a total of 2 cycles)on the basis of radiotherapy,and group C was treated with radiotherapy alone.The course of treatment was 6 weeks.The clinical efficacy was evaluated in three groups from the aspects of objective remission rate,swallowing function score,incidence rates of adverse drug reactions,5-year progression-free survival(PFS),5-year overall survival(OS)and 5-year survival rate.Results A totol of 130 patients were indued,including 43 cases in group A,45 cases in group B and 42 cases in group C.The objective remission rates of group A,B and C were 81.40％(35/43),75.56％(34/45)and 54.76％(23/42),which were higher in group A and B than in group C(P＜0.05),but there was no significant difference between group A and B(P＞0.05).After treatment,the swallowing function scores of group A,group B and group C were(2.02±0.46),(2.23±0.5)and(2.65±0.62)scores,respectively.The swallowing function scores of group A and group B were lower than those of group C(all P＜0.05),but there was no significant difference between group A and group B(P＞0.05).The median PFS of group A,group B and group C were 15.9,15.1 and 12.4 months,respectively.The PFS of group A and group B were significantly longer than that of group C(all P＜0.05),but there was no significant difference between group A and group B(P＞0.05).The median OS of group A,group B and group C were 20.2,18.4 and 16.3 months,respectively.Group A and group B were significant longer than group C,and group A was significant longer than group B(all P＜0.05).The survival rates of group A,group B and group C were 18.60％(8 cases/43 cases),13.33％(6 cases/45 cases)and 11.90％(5 cases/42 cases),with no statistically significant difference(P＞0.05).The incidence of adverse reactions in group A was 13.95％(6 cases/43 cases),which was lower than 38.10％(16 cases/42 cases)in group C and 33.33％(15 cases/45 cases)in group B(P＜0.05),while there was no significant difference between group C and group B(P＞0.05).Conclusion Both END and OP can enhance the objective remission rate,and improve the swallowing function and quality of life in elderly patients with LAEC radiotherapy,but END has better clinical efficacy in terms of safety and long-term survival.关键词
重组人血管内皮抑制素注射液/替吉奥片/放疗/局部晚期食管癌/老年/生存率Key words
recombinant human endostatin injection/tegafur/gimeracil/oteracil potassium/radiotherapy/locally advanced esophageal cancer/elderly/survival rate分类
医药卫生引用本文复制引用
余云鹏,戴春华,凌锐..重组人血管内皮抑制素治疗老年局部晚期食管癌患者的临床研究[J].中国临床药理学杂志,2025,41(14):1983-1987,5.基金项目
白求恩·精医求精-晚期实体瘤科研基金资助项目(STLKY0058) （STLKY0058）
